Actively Recruiting
A Phase II Study Comparing Intraperitoneal and Intravenous Chemotherapy After Surgery and Heated Chemotherapy for Malignant Peritoneal Mesothelioma
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-07-21
64
Participants Needed
13
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating whether chemotherapy given directly into the abdomen intraperitoneal or through the veins intravenous after surgery and heated chemotherapy treatment is more effective for people with malignant peritoneal mesothelioma. This phase 2 trial compares these two treatment methods to see if one may lead to better outcomes for this rare cancer that affects the lining of the abdomen. Participants will receive either intravenous chemotherapy with pemetrexed and cisplatin or carboplatin if needed for 4 to 6 cycles or intraperitoneal chemotherapy through a catheter placed in the abdomen after surgery and heated chemotherapy. The intraperitoneal treatment starts once the patients condition stabilizes, allowing direct delivery of pemetrexed with either cisplatin or carboplatin. During the study, participants will be closely monitored for cancer progression for up to 24 months. Researchers will assess treatment effectiveness by measuring progression-free survival. Patients will undergo regular clinical evaluations and laboratory tests to track their response and safety. The total study duration extends until September 2028, ensuring thorough follow-up and outcome assessment.
CONDITIONS
Brief Title
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Research Team
G
Garrett Nash, MD
M
Michael Offin, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
